(Q42324127)
Statements
Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats (English)
Christoph Campregher
Clemens Honeder
Heekyung Chung
John M Carethers
1 reference
1 reference